Reagan 发表于 2025-3-21 18:01:21

书目名称Antirheumatic Therapy: Actions and Outcomes影响因子(影响力)<br>        http://figure.impactfactor.cn/if/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes影响因子(影响力)学科排名<br>        http://figure.impactfactor.cn/ifr/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes网络公开度<br>        http://figure.impactfactor.cn/at/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes网络公开度学科排名<br>        http://figure.impactfactor.cn/atr/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes被引频次<br>        http://figure.impactfactor.cn/tc/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes被引频次学科排名<br>        http://figure.impactfactor.cn/tcr/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes年度引用<br>        http://figure.impactfactor.cn/ii/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes年度引用学科排名<br>        http://figure.impactfactor.cn/iir/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes读者反馈<br>        http://figure.impactfactor.cn/5y/?ISSN=BK0158659<br><br>        <br><br>书目名称Antirheumatic Therapy: Actions and Outcomes读者反馈学科排名<br>        http://figure.impactfactor.cn/5yr/?ISSN=BK0158659<br><br>        <br><br>

口味 发表于 2025-3-21 22:54:22

Progress in Inflammation Researchhttp://image.papertrans.cn/a/image/158659.jpg

慢跑鞋 发表于 2025-3-22 00:28:30

Multiscale , Modeling of Cartilage Injuriesll drugs, the chemical properties of the DMARD and corticosteroids are important aspects of their pharmacology. In this chapter, the medicinal chemistry of the various DMARD is discussed. The coverage includes the chemical factors that affect their handling by the body. In addition to the DMARD disc

到婚嫁年龄 发表于 2025-3-22 04:39:04

Brianne K. Connizzo,Lin Han,Robert L. Sahheir patients are faced with a variety of therapeutic choices in the management of RA and must make decisions about specific disease-modifying antirheumatic drugs (DMARDs), including potential combinations of different agents. A careful balance of short-term and long-term benefits and risks must be

NAVEN 发表于 2025-3-22 09:10:40

http://reply.papertrans.cn/16/1587/158659/158659_5.png

委屈 发表于 2025-3-22 13:54:36

https://doi.org/10.1007/978-3-319-48899-8ponse. However, biologic agents are frequently immunogenic, requiring complex and labor intensive production processes and parenteral administration, resulting in high costs which limit both availability and access to treatment.

未开化 发表于 2025-3-22 19:04:10

http://reply.papertrans.cn/16/1587/158659/158659_7.png

EVICT 发表于 2025-3-23 00:35:28

http://reply.papertrans.cn/16/1587/158659/158659_8.png

致敬 发表于 2025-3-23 02:52:48

http://reply.papertrans.cn/16/1587/158659/158659_9.png

无力更进 发表于 2025-3-23 07:22:47

Advances in Applied Neurological Sciences 6-mercaptopurine and this is metabolised by hypoxanthine guanine phosphoribosyl transferase (HGPRT) to produce the active metabolites thioinosinic and thioguanylic acid. These metabolites inhibit intracellular function by interfering with adenine and guanine ribonucleotide production through suppre
页: [1] 2 3 4 5 6 7
查看完整版本: Titlebook: Antirheumatic Therapy: Actions and Outcomes; Richard O. Day,Daniel E. Fürst,Barry Bresnihan Book 2005 Birkhäuser Basel 2005 Arthritis.auto